HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTFA Weighs In As Prop 65 Amicus Brief Filed In Calif. Supreme Court

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association amicus curiae brief in defense of nicotine-replacement therapy manufacturers involved in California Prop 65 litigation reflects the group's concern the labeling conflict involved could extend to other OTC drugs

You may also be interested in...



German Firm Hopes To Drill Into U.S. Market With Anti-Dandruff Ingredient

Dermatology ingredient manufacturer Ichthyol-Gesellschaft is looking to introduce sodium shale oil sulfonate into FDA's OTC monograph as an ingredient that is generally recognized as safe and effective in treating dandruff

German Firm Hopes To Drill Into U.S. Market With Anti-Dandruff Ingredient

Dermatology ingredient manufacturer Ichthyol-Gesellschaft is looking to introduce sodium shale oil sulfonate into FDA's OTC monograph as an ingredient that is generally recognized as safe and effective in treating dandruff

Calif. Supreme Court Rules In Favor Of Glaxo, FDA On Prop 65 Warnings

State regulations that conflict with FDA drug labeling are preempted by federal law, the California Supreme Court ruled April 15 in a case challenging the state's mandatory Prop 65 warning requirements for nicotine replacement therapy (NRT) products

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel